Filter announcements
Loading...
Themis Medicare is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.
Themis Medicare's registrar confirmed no requests to re-lodge physical share transfers were received during December.
Themis Medicare confirmed zero re-lodgement requests for physical share transfers during the recent two-month window, indicating smooth administrative processing for physical shareholders.
Themis Medicare reports no requests for re-lodgement of physical share transfers were received during the special compliance window period. This indicates smooth operations with no outstanding physical share transfer issues.
Themis Medicare is supporting the 'Saksham Niveshak' campaign, urging shareholders to update KYC details and bank mandates. This initiative aims to help shareholders claim their unpaid/unclaimed dividends.
Themis Medicare and its subsidiary Gujarat Themis Biosyn have called off their merger plan. Gujarat Themis Biosyn will now focus on boosting its fermentation-based pharma intermediates and API business via capacity expansion and partnerships. Meanwhile, Themis Medicare will prioritize strengthening its core domestic formulations segment for steady growth. This strategic...